Business Wire

Bluehole New Consumption Publishes a Feature Story on Recent Vaping Regulation Updates

Share

China’s leading vaping media, Bluehole New Consumption, today published a feature story on recent vaping regulation updates in the UK, the US and Malaysia. As vaping accepted by more and more health regulators, the industry will witness a more concentrated and standardized market.

Here below is the full article in English:

On October 29, 2021, the U.K government agency, Medicines and Healthcare Products Regulatory Agency (MHRA) announced that NHS could soon prescribe e-cigarettes to help tobacco smokers quit, inviting e-cigarette manufacturers to submit products to undergo the same approval process as prescribed medicines. It could make England the first country to prescribe medicinally licensed e-cigarettes. Under such a circumstance, “A medically licensed e-cigarette would have to pass even more rigorous safety checks than those required for them to be sold commercially,” according to BBC.

On the same day, the Malaysian government announced to impose excise duty on nicotine vapor products. The managing director of British America Tobacco (BAT) Malaysia, Nedal Salem, said this indicates the Malaysian government is looking to legalize nicotine vapor products: “Regulation will not only allow vape users access to reduced-risk alternatives to smoking, but also ensure the products used are compliant to quality and safety standards.”

Meanwhile, in October, the U.S Food and Drug Administration (FDA) has granted marketing orders for Vuse Solo and accompanying tobacco flavored e-liquid pods, making it the first set of e-cigarette authorized for sale by the FDA.

From the UK to Malaysia and the U.S, E-cigarette is accepted by more and more health regulators around the world as an effective harm-reduction tool to improve public health.

As BAT Malaysia states, regulation could positively accelerate healthy development of the vaping industry for setting higher quality requirements and safety standards for products. Moreover, regulation measures, such as the marketing authorization and prescription evaluation, could be deemed the regulators’ acknowledgement of the products’ public health benefits.

Besides, Mitch Zeller, director of the FDA Center for Tobacco Products, said that “many of the tobacco product reviews are in final stages,” at a virtual conference hosted by the Food and Drug Law Institute on October 27. However, the agency so far has only authorized three products for their substantial evidence of harm reduction while issuing marketing denial orders for 200 thousand products.

Vuse is currently in a lead position to pass the Premarket Tobacco Product Applications (PMTA) process. It showcases that the FDA (and perhaps other regulators) is more likely to trust and approve products made by market leaders for assured public health benefits and reliability proved by sufficient scientific data.

The FDA’s rigorous requirements for products are also applied to manufacturers. SMOORE, the world’s largest vaping manufacturer, is the strategic supplier of VUSE. It features PMTA-related non-clinical evaluation capabilities, including physical testing, chemical testing and health risk assessment. Moreover, SMOORE’s CNAS tests have also expanded to 134.

As the regulatory framework outlines a higher entry barrier for the industry, the global vaping industry will witness a more standardized and concentrated market where industry leaders, such as BAT and SMOORE, will further strengthen their leading positions. Meanwhile, the whole industry and the supply chain will benefit from such a well-regulated and standardized market in turn.

To read the original article, please visit: https://www.bluehole.com.cn/news/detail/47350

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bluehole New Consumption Contact Info:
(+86)18612693874
CHEN ZHONG

SMOOR
Frankie Chen
(+86)13530848319
frankie.chen@smoorecig.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sai Life Sciences Opens Dedicated Facility for Veterinary APIs in Bidar, India18.9.2025 19:22:00 EEST | Press release

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), an innovator-focused Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the opening of Unit VI, a dedicated facility for Veterinary Active Pharmaceutical Ingredient (API) production, in Bidar, India. Located alongside Unit IV, the company’s flagship API manufacturing site, Unit VI has been established exclusively for veterinary APIs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918612071/en/ Sai Life Sciences’ Veterinary APIs Unit in Bidar, India. The new facility is designed to meet the highest standards of safety, sustainability, and regulatory compliance, ensuring the production of high-quality APIs for veterinary applications. With this expansion, Sai Life Sciences aims to provide efficient and scalable manufacturing solutions to leading global animal health companies. Making the announcement, Krishna Kanumuri, CEO & Managing Direct

Celltrion Announces Commercial Availability of Omlyclo™ Across Europe at EADV 202518.9.2025 18:45:00 EEST | Press release

Celltrion, Inc. today showcased its longstanding commitment to expanding its biosimilar portfolio in the field of immuno-dermatology by attending the 2025 European Academy of Dermatology and Venereology (EADV) Congress, held 17-20 September in Paris, France. Following the European Commission (EC) approval of Omlyclo™, the first and only omalizumab biosimilar in Europe in May 2024, Omlyclo™ will be commercially available starting in Norway, with subsequent rollouts in European countries. As part of Celltrion’s mission to advance knowledge and understanding in dermatology, especially in chronic spontaneous urticaria (CSU), the company hosted satellite symposium presenting the results of the global Phase III clinical trial of Omlyclo™. The global Phase III clinical trial involved 619 patients with CSU, following them up to week 40. Patients were randomized to receive 300 mg or 150 mg of Omlyclo™, or reference product, every 4 weeks. Starting from week 12, patients who received Omlyclo™ we

Setting the Standard: AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’18.9.2025 17:40:00 EEST | Press release

AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918372780/en/ AMRA Medical Recognized as one of TIME Magazine’s ‘World’s Top HealthTech Companies’ The selection, which comes just one week after celebrating AMRA’s 15 years of progress and innovation within the body composition space, highlights AMRA’s long-standing commitment to becoming a global leader in health informatics. By delivering detailed, reproducible insights within fat distribution and muscle composition, AMRA’s MRI-based technology is helping clinicians, researchers, and healthcare organizations unlock new levels of understanding across the metabolic and musculoskeletal sectors. “Being recognized by

illumynt, a CNE Direct Company, Is Pleased to Announce the Promotion of Jörg Herbarth to Chief Executive Officer (CEO)18.9.2025 17:30:00 EEST | Press release

illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Executive Officer (CEO). Jörg has been a key member of illumynt’s executive leadership team since joining in June 2022, most recently serving as Chief Operating Officer. In his new role as CEO, Jörg will spearhead illumynt’s mission to become the number one provider of AI- and data-centric IT Asset Disposition (ITAD) solutions worldwide. Paul Knight, illumynt’s current CEO, will transition to the role of Founder & Chairman. In this capacity, Paul will continue to support the executive team with strategic guidance, while Jörg assumes full leadership of day-to-day operations and global expansion initiatives. Mr. Knight had come out of retirement a year ago to undertake some new initiatives and advance the company's strategic direction. With some necessary changes having taken place- he is thrilled to facilitate this transition to a reduced role again. Under Jörg’s leadership, illumynt will cont

Textron Aviation Broadens Aftermarket Connectivity Solutions for Cessna Citation Latitude by Offering Starlink High-Speed Internet18.9.2025 16:30:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced an additional high-speed internet connectivity solution for the Cessna Citation Latitude following the Federal Aviation Administration’s (FAA) issuance of AeroMech’s Supplemental Type Certificate (STC) for Starlink high-speed internet connectivity. AeroMech’s STC utilizes Starlink’s constellation of Low Earth Orbit (LEO) satellites to provide more reliable connectivity over land, water and remote areas, where traditional in-flight Wi-Fi may not have service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918380069/en/ Textron Aviation broadens aftermarket connectivity solutions for Cessna Citation Latitude by offering Starlink high-speed internet (Photo Credit: Textron Aviation) “With Starlink connectivity now available as an upgrade, Citation Latitude customers can enjoy a seamless, high-speed in-flight experience that keeps them connected in more

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye